ARTV Stock Risk & Deep Value Analysis
Artiva Biotherapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on ARTV
We analyzed Artiva Biotherapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ARTV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈ARTV Performance Overview3yr weekly
Unlock ARTV Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
ARTV Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Artiva Biotherapeutics Inc (ARTV)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$102.60M
ARTV Deep Value Analysis
Compare ARTV to Similar Stocks
See how Artiva Biotherapeutics Inc stacks up against related companies in our head-to-head analysis.
ARTV Red Flags & Warning Signs
Premium- ⚠
Failure to secure adequate financing, leading to further dilution or operational shutdown
- ⚠
Negative or inconclusive clinical trial results for AB-101 or other pipeline candidates
- ⚠
Competitive advancements from other allogeneic cell therapy developers
- ⚠
Regulatory delays or unfavorable rulings for NK cell therapies
Unlock ARTV Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
ARTV Financial Health Metrics
Market Cap
$102.60M
ARTV Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding (if clinical validation and IP protection are successful)
Moat Sources
2 Identified
The moat's durability is currently dependent on successful clinical trials, which will validate the platform and attract further investment/partnerships. Strong patent protection around their specific NK cell lines and manufacturing will be key.
ARTV Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
ARTV Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated mid-March 2026)
- •Announcement of new financing round (critical, urgent)
- •Presentation of updated AB-101 Phase 1/2 clinical data
Medium-Term (6-18 months)
- •Expansion or new terms of collaboration with Merck
- •Initiation of additional clinical trials for pipeline candidates
- •Strategic partnership with a new large pharmaceutical company
Long-Term (18+ months)
- •Advancement of lead candidates into pivotal Phase 3 studies
- •Potential market approval and commercialization of first off-the-shelf NK cell therapy
- •Industry-wide adoption of allogeneic cell therapies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
ARTV Bull Case: What Could Go Right
- ✓
Announcement of a substantial equity financing round or non-dilutive partnership funding (positive)
- ✓
Positive Phase 1/2 clinical data updates for AB-101 (positive)
- ✓
Continued depletion of cash reserves without financing (negative, increases shutdown risk)
- ✓
Any indications of significant trial delays or safety concerns (negative)
Bull Case Analysis
See what could go right with Premium
Never miss a move on ARTV
Create a free account to set price alerts and get notified on Telegram when ARTV hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Artiva Biotherapeutics Inc (ARTV)?
As of January 16, 2026, Artiva Biotherapeutics Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Artiva Biotherapeutics Inc?
Artiva Biotherapeutics Inc's market capitalization is approximately $102.6M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Artiva Biotherapeutics Inc use?
ARTV is the ticker symbol for Artiva Biotherapeutics Inc. The company trades on the NGM.
What is the risk level for ARTV stock?
Our analysis rates Artiva Biotherapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the ARTV DVR analysis updated?
Our AI-powered analysis of Artiva Biotherapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on January 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.